Last updated: February 4, 2026
Litigation Summary and Analysis for LEO Pharma A/S v. Glenmark Pharmaceuticals Ltd. | 1:20-cv-01359
Case Overview
LEO Pharma A/S initiated litigation against Glenmark Pharmaceuticals Ltd. in the United States District Court for the District of New Jersey under case number 1:20-cv-01359. The patent infringement suit concerns topical dermatological products, specifically relating to patents covering formulations designed for treating psoriasis and other skin conditions.
Core Patent and Claims
The litigation primarily involves U.S. Patent No. 9,947,960, issued to LEO Pharma, which claims specific topical compositions with unique surfactant and alcohol components designed to improve drug stability and skin absorption. The patent is set to expire in 2032.
Claims include:
- Composition with specific weight ratios of active pharmaceutical ingredient (API) and excipients.
- Use of particular surfactants to enhance drug penetration.
- Stability of formulations under various storage conditions.
Allegations
LEO Pharma alleges Glenmark has infringed on the '960 patent by manufacturing, marketing, and selling competing topical formulations within the claimed scope. The complaint asserts that Glenmark’s product, marketed as a generic alternative, directly violates the patent rights and unjustly benefits from patent exclusivity.
Defenses and Counterclaims
Glenmark has argued that the patent is invalid based on:
- Obviousness under 35 U.S.C. § 103, citing prior art references that disclose similar compositions.
- Lack of novelty, referencing earlier patent applications and publications.
- Non-infringement, claiming the accused formulations differ materially in composition or method of use.
Glenmark also filed a counterclaim seeking a declaratory judgment of patent invalidity.
Procedural Status
As of the latest update (March 2023), the case remains in the pre-trial phase with discovery ongoing. Both parties have filed preliminary motions, including a motion for claim construction from LEO Pharma and Glenmark’s motion to dismiss aspects of the case based on alleged patent invalidity.
Strategic Significance
LEO Pharma's patent protections aim to defend proprietary formulations that offer improved stability and efficacy. Glenmark’s challenge hinges on demonstrating that the patent’s claims are obvious or lack novelty, which could potentially invalidate key proprietary rights.
The outcome may influence the scope of patent rights available to pharmaceutical innovators in dermatological therapies and set precedents relating to formulation patents in the generics sector.
Industry Context and Implications
The legal dispute exemplifies ongoing tension between brand-name pharmaceutical companies and generic manufacturers. Courts increasingly scrutinize formulation patents, particularly concerning obviousness and patentable subject matter.
For stakeholders, this litigation underscores:
- The importance of strong, non-obvious claims.
- The risk of patent invalidation based on evidence of prior art.
- The strategic value of patent litigation as a competitive tool in dermatological drug markets.
Key Dates and Timeline
| Date |
Event |
| May 26, 2020 |
Complaint filed by LEO Pharma |
| August 2020 |
Glenmark files motion to dismiss/invalidate patent claims |
| December 2021 |
Claim construction procedures initiated |
| March 2023 |
Ongoing discovery; case active in pre-trial motions |
Potential Outcomes
- Patent uphold: Court finds patent valid and infringed, leading to injunctions, damages, or royalties.
- Patent invalidation: Court finds patents obvious or not novel, allowing Glenmark to market generic products freely.
- Settlement: Parties resolve through licensing, cross-licenses, or settlement agreements before trial.
Conclusion
The case remains pending with no final judgment issued. Its resolution depends on patent validity arguments, infringement assessments, and procedural developments.
Key Takeaways
- The case involves patent rights protecting specific topical dermatology formulations.
- Glenmark challenges both patent validity and infringement claims.
- The ruling will impact patent enforceability for formulation-based innovations.
- Patent validity hinges on prior art and obviousness defenses.
- The dispute exemplifies the ongoing patent enforcement efforts in the dermatology segment.
FAQs
1. What are common grounds for patent invalidation in pharmaceutical litigation?
Obviousness, lack of novelty, insufficient disclosure, or patent claims not meeting statutory requirements.
2. How does the court determine patent infringement in formulation patents?
By comparing the claims' scope with the accused product’s composition and use to see if the accused formulation fits within the patent claims.
3. What is the significance of the '960 patent’s expiration date?
It sets a legal boundary for patent protection, after which the patent no longer grants exclusivity.
4. How might Glenmark’s validity challenge impact the dermatological market?
If successful, it could open the market for generic formulations, reducing costs and increasing access.
5. What strategic steps can patent holders take to defend formulation patents?
Strengthen patent claims with detailed disclosures, conduct prior art searches, and pursue early litigation or settlement.
Citations
- U.S. Patent No. 9,947,960.
- Court docket: 1:20-cv-01359, District of New Jersey.
- Pharmaceutical patent litigation trends, Bloomberg Law.
- Patent invalidity defenses, U.S. Court of Appeals decisions.
